NO950474L - Methods of endotoxin prophylaxis and therapy - Google Patents

Methods of endotoxin prophylaxis and therapy

Info

Publication number
NO950474L
NO950474L NO950474A NO950474A NO950474L NO 950474 L NO950474 L NO 950474L NO 950474 A NO950474 A NO 950474A NO 950474 A NO950474 A NO 950474A NO 950474 L NO950474 L NO 950474L
Authority
NO
Norway
Prior art keywords
endotoxin
prophylaxis
therapy
methods
reconditioned
Prior art date
Application number
NO950474A
Other languages
Norwegian (no)
Other versions
NO950474D0 (en
Inventor
Daniel M Levine
Thomas S Parker
Albert L Rubin
Original Assignee
Rogosin Inst The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/928,930 external-priority patent/US5344822A/en
Application filed by Rogosin Inst The filed Critical Rogosin Inst The
Publication of NO950474D0 publication Critical patent/NO950474D0/en
Publication of NO950474L publication Critical patent/NO950474L/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives terapi og profylakse av endotoksin- forårsaket toksisitet. Dette oppnås ved å administrere et lipid som det aktuelle endotoksin forbinder seg med, for- trinnsvis sammen med et peptid som ikke er et apolipo- protein. Fortrinnsvis administreres de to bestanddeler i form av en rekondisjonert partikkel, selv om dette på ingen måte er nødvendig.Therapy and prophylaxis of endotoxin-induced toxicity are described. This is achieved by administering a lipid to which the relevant endotoxin binds, preferably together with a peptide which is not an apolipoprotein. Preferably, the two components are administered in the form of a reconditioned particle, although this is by no means necessary.

NO950474A 1992-08-12 1995-02-09 Methods of endotoxin prophylaxis and therapy NO950474L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/928,930 US5344822A (en) 1992-08-12 1992-08-12 Methods useful in endotoxin prophylaxis and therapy
PCT/US1993/007453 WO1994004177A1 (en) 1992-08-12 1993-08-09 Methods useful in endotoxin prophylaxis and therapy

Publications (2)

Publication Number Publication Date
NO950474D0 NO950474D0 (en) 1995-02-09
NO950474L true NO950474L (en) 1995-04-07

Family

ID=26786943

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950474A NO950474L (en) 1992-08-12 1995-02-09 Methods of endotoxin prophylaxis and therapy

Country Status (1)

Country Link
NO (1) NO950474L (en)

Also Published As

Publication number Publication date
NO950474D0 (en) 1995-02-09

Similar Documents

Publication Publication Date Title
AU1658392A (en) Manifold
AU7261994A (en) Hydrazino-type radionuclide chelators having an n3s configuration
ES2144119T3 (en) USE OF NON-STEROID CYCLOOXYGENASE INHIBITORS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HIGH INTRAOCULAR PRESSURE.
BG102417A (en) Method and pharmaceutical composition for lipid concentration regulation
BR9406814A (en) Immunoglobulin g concentrate for therapeutic use and the production process of said concentrate
EP0784471A4 (en) Multi-faceted method to repress reproduction of latent viruses in humans and animals
IE852906L (en) Meso-porphyrins in cancer therapy
NO931766D0 (en) TOPICAL PREPARATIONS FOR TRANSDERMAL DELIVERY OF PRESERVANT MEDICINAL DERIVATIVES OF MORPHINE
AU2172588A (en) Conjugates of cytokines with immunoglobulins
NO20092860L (en) 2, 6 dioxopiperidine and pharmaceutical compositions containing them
PT1523982E (en) Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
BG101118A (en) Therapeutical compounds
DK0914144T3 (en) Therapeutic uses of BPI protein products for human meningococcemia
AU2724492A (en) Antibodies in immunosuppression
PL330910A1 (en) Mode of administering inhibitors of h+, k+ - atpase
NZ301645A (en) (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases
AU5973594A (en) Syringe for administering a given number of injections
AU7970894A (en) Method of treating depressed reticuloendothelial system function
NO950474L (en) Methods of endotoxin prophylaxis and therapy
DE3685484D1 (en)
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
AU6258898A (en) Treatment of chronic inflammatory diseases with cm101/gbs toxin
ES8405621A1 (en) A TUMORAL IMMUNOPREPARATION.
AR005866A1 (en) ANTIOXIDANT PHARMACEUTICAL COMPOSITION
NO934375L (en) Crystal forms of optically active isoindolines and their use